Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF

Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference

Elafibranor improves diet-induced nonalcoholic steatohepatitis

PDF) Elafibranor improves diet-induced nonalcoholic

Frontiers Current Understanding of Molecular Pathophysiology of

Liraglutide shows superior cardiometabolic benefits than

Improving insights into the heterogeneous HFpEF syndrome through

Neurohormonal Modulation in HFpEF

Physiogenex on LinkedIn: Physiogenex is at ILC-EASL 2022 in London

Heart failure in type 2 diabetes: current perspectives on

Conference - Cardiomedex